In the SCALE Sleep Apnea RCT, liraglutide 3.0 mg was associated with a significant reduction of apnea-hypopnea index (AHI) compared to placebo (6.1 events per hour, 95% 11 to 1.2 events per hour) at 32 weeks in patients with moderate to severe OSA not on positive airway pressure 20
Off-Label Uses of Semaglutide 5.1 Semaglutide for PCOS and Metabolic Regulation 5.2 Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) 5.3 Binge Eating Disorder and Appetite Dysregulation 5.4 Weight Loss in Non-Obese Individuals (Clinical Considerations) 5.5 Cardiovascular Disease Prevention Beyond Approved Scope 5.6 Adjunct in Metabolic Syndrome Management 5.7 Potential Neuroprotective and Anti-Inflammatory Roles (Emerging Research) 6
Patients with both type 2 diabetes and obesity may find the drug especially helpful, as it targets two significant health challenges simultaneously
Why India Is Keeping Innovator Companies Awake Unlike the US and Europe, where: Patents remain strong till 2031+ Biosimilar entry is tightly regulated Payors and insurers manage pricing and access India is different - and heres why companies like Novo Nordisk are cautious: 1
Compounded medications carry their own separate risks (concentration variability, no FDA review)
AOD-9604 offers a distinct, IGF-1-independent lipolysis mechanism worth studying in its own right